ONL Therapeutics
ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. They focus on protecting key retinal cells from Fas-mediated cell death using innovative technology, aiming to address major unmet medical needs in retinal diseases such as retinal detachment, glaucoma, AMD, and IRD.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Investigational intravitreal Fas-pathway inhibitor (ophthalmic solution)
An investigational intravitreal ophthalmic formulation designed to inhibit Fas-mediated retinal cell death; evaluated in multiple Phase 1/1b and Phase 2 clinical trials for retinal detachment, open-angle glaucoma, and geographic atrophy associated with AMD.
Investigational gene therapy approach for Fas inhibition
A preclinical-to-development gene therapy program intended to achieve Fas pathway inhibition as an alternative modality to small-molecule/peptide inhibitors.
Investigational intravitreal Fas-pathway inhibitor (ophthalmic solution)
An investigational intravitreal ophthalmic formulation designed to inhibit Fas-mediated retinal cell death; evaluated in multiple Phase 1/1b and Phase 2 clinical trials for retinal detachment, open-angle glaucoma, and geographic atrophy associated with AMD.
Investigational gene therapy approach for Fas inhibition
A preclinical-to-development gene therapy program intended to achieve Fas pathway inhibition as an alternative modality to small-molecule/peptide inhibitors.
Services
Design and conduct of multicenter ophthalmic clinical trials including safety, pharmacokinetics, dose-ranging and efficacy assessments.
Management of trial data and application of imaging analysis workflows, including AI-assisted image analysis for retinal endpoints.
Design and conduct of multicenter ophthalmic clinical trials including safety, pharmacokinetics, dose-ranging and efficacy assessments.
Management of trial data and application of imaging analysis workflows, including AI-assisted image analysis for retinal endpoints.
Expertise Areas
- Retinal neuroprotection
- Ophthalmic clinical trial management
- Intravitreal formulation development
- CMC and clinical trial material production
Key Technologies
- Fas-pathway inhibition (small-molecule/peptide)
- Intravitreal ophthalmic delivery
- Ophthalmic solution formulation
- Gene therapy vectors for pathway inhibition
News & Updates
Presentation on Fas Inhibition with ONL1204 Ophthalmic Solution for the Treatment of Geographic Atrophy by Dr. Baruch D. Kuppermann.
Presentation on Fas Inhibition with ONL1204 for the Treatment of Open-Angle Glaucoma by Dr. Jeffrey Goldberg.
Keynote lecture on Photoreceptor Cell Death by Dr. David N. Zacks, CSO of ONL Therapeutics.
Presentation on Fas Inhibition with ONL1204 Ophthalmic Solution for the Treatment of Geographic Atrophy by Dr. Baruch D. Kuppermann.
Presentation on Fas Inhibition with ONL1204 for the Treatment of Open-Angle Glaucoma by Dr. Jeffrey Goldberg.
Keynote lecture on Photoreceptor Cell Death by Dr. David N. Zacks, CSO of ONL Therapeutics.